CN1452633A - 哺乳动物基因、相关试剂及方法 - Google Patents

哺乳动物基因、相关试剂及方法 Download PDF

Info

Publication number
CN1452633A
CN1452633A CN01815161A CN01815161A CN1452633A CN 1452633 A CN1452633 A CN 1452633A CN 01815161 A CN01815161 A CN 01815161A CN 01815161 A CN01815161 A CN 01815161A CN 1452633 A CN1452633 A CN 1452633A
Authority
CN
China
Prior art keywords
leu
val
pro
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01815161A
Other languages
English (en)
Chinese (zh)
Inventor
C·L·帕哈姆
D·M·戈尔曼
H·库拉塔
N·阿赖
T·R·萨纳
J·D·马特森
E·E·穆菲
C·萨夫科尔
J·格雷恩
K·M·史密斯
T·K·麦克拉纳汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1452633A publication Critical patent/CN1452633A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN01815161A 2000-09-08 2001-09-07 哺乳动物基因、相关试剂及方法 Pending CN1452633A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23126700P 2000-09-08 2000-09-08
US60/231,267 2000-09-08

Publications (1)

Publication Number Publication Date
CN1452633A true CN1452633A (zh) 2003-10-29

Family

ID=22868480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01815161A Pending CN1452633A (zh) 2000-09-08 2001-09-07 哺乳动物基因、相关试剂及方法

Country Status (9)

Country Link
US (6) US7060800B2 (enExample)
EP (2) EP2298789B1 (enExample)
JP (2) JP2004509617A (enExample)
CN (1) CN1452633A (enExample)
AT (1) ATE549347T1 (enExample)
AU (1) AU2001294541A1 (enExample)
CA (1) CA2419979A1 (enExample)
MX (1) MXPA03002049A (enExample)
WO (1) WO2002020569A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229226A (zh) * 2019-05-23 2019-09-13 西安医学院 一种slfn11截断肽及其应用和药物组合物

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1578901A (en) * 1999-11-05 2001-06-06 Human Genome Sciences, Inc. 24 human secreted proteins
EP1234035B1 (en) 1999-12-03 2010-02-24 ZymoGenetics, Inc. Human cytokine receptor
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
ATE342980T1 (de) 2000-08-08 2006-11-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
US7358353B2 (en) * 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
DE60126495T2 (de) 2000-08-22 2007-11-29 Agensys, Inc., Santa Monica Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
CN1452633A (zh) * 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
DK1356046T3 (da) * 2000-11-28 2010-03-01 Zymogenetics L L C Cytokinreceptor zcytoR19
EP1339847A2 (en) * 2000-11-28 2003-09-03 Amgen, Inc. Transforming growth factor-beta-related molecules and uses thereof
WO2002077174A2 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
CA2462687A1 (en) * 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
WO2003083062A2 (en) 2002-03-22 2003-10-09 Zymogenetics, Inc. Anti-il-tif antibodies and methods of using in inflammation
ES2356307T3 (es) * 2002-04-19 2011-04-06 Zymogenetics, L.L.C. Procedimientos para detectar o modular la interacción de un receptor de citocina con su ligando.
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7135170B2 (en) 2002-10-23 2006-11-14 Zymogenetics, Inc. Methods for treating viral infection using IL-28 and IL-29
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2343315A3 (en) * 2003-02-10 2011-11-23 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
PT2251353E (pt) 2003-08-07 2013-05-07 Zymogenetics Inc Preparações homogéneas de il-28 e il-29
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
GB0325038D0 (en) * 2003-10-27 2003-12-03 Ares Trading Sa Protein
CA2558829C (en) 2004-04-02 2014-03-11 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29 cysteine mutants
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2574564C (en) 2004-07-29 2013-04-16 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer and autoimmune disorders
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
DK1812476T3 (da) 2004-10-22 2010-10-25 Zymogenetics Inc Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
GB0423973D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa C1q related points
CA2603671C (en) * 2005-04-26 2012-03-27 Laboratoires Serono S.A. Insp163 polypeptides for the treatment or prevention of cancer and arthritis
US20070020227A1 (en) 2005-07-20 2007-01-25 Sheppard Paul O Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
LT3604510T (lt) 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
EP2482798A1 (en) * 2009-10-01 2012-08-08 Alcon Research, Ltd. Olopatadine compositions and uses thereof
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
US9228006B2 (en) 2012-03-16 2016-01-05 University Health Network Methods and compositions for modulating Toso activity
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102274722B1 (ko) 2012-08-23 2021-07-09 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체
NZ707831A (en) 2012-11-13 2018-11-30 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
US20150250853A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for modifying the immune response
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EP3565834B1 (en) 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2021007260A2 (en) 2019-07-08 2021-01-14 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88426A (en) 1869-03-30 Improved velocipede
US2736896A (en) 1951-12-04 1956-02-28 Sperry Rand Corp Horn antenna system
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
CN1452633A (zh) * 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
US11068393B2 (en) 2019-10-17 2021-07-20 Microsoft Technology Licensing, Llc Enhanced concurrency garbage collection stack scanning

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229226A (zh) * 2019-05-23 2019-09-13 西安医学院 一种slfn11截断肽及其应用和药物组合物
CN110229226B (zh) * 2019-05-23 2023-04-11 西安医学院 一种slfn11截断肽及其应用和药物组合物

Also Published As

Publication number Publication date
US8426573B2 (en) 2013-04-23
MXPA03002049A (es) 2003-07-24
EP1315743A2 (en) 2003-06-04
JP2004509617A (ja) 2004-04-02
US20110165165A1 (en) 2011-07-07
US7427668B2 (en) 2008-09-23
US20100104576A1 (en) 2010-04-29
US20120164147A1 (en) 2012-06-28
US7060800B2 (en) 2006-06-13
US7893211B2 (en) 2011-02-22
US8148507B2 (en) 2012-04-03
WO2002020569A3 (en) 2003-01-23
EP2298789A1 (en) 2011-03-23
US20020142292A1 (en) 2002-10-03
US20050186620A1 (en) 2005-08-25
WO2002020569A2 (en) 2002-03-14
CA2419979A1 (en) 2002-03-14
US7696317B2 (en) 2010-04-13
US20090155242A1 (en) 2009-06-18
ATE549347T1 (de) 2012-03-15
AU2001294541A1 (en) 2002-03-22
EP1315743B1 (en) 2012-11-07
JP2009039124A (ja) 2009-02-26
EP2298789B1 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
CN1452633A (zh) 哺乳动物基因、相关试剂及方法
CN1444652A (zh) 哺乳动物受体蛋白;相关试剂和方法
CN1225555C (zh) 人Toll样受体蛋白、相关试剂和方法
CN1575337A (zh) 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法
CN1184315C (zh) 包含死亡结构域的受体－5
CN1052510C (zh) 白细胞介素－10的哺乳动物受体
CN1105187C (zh) 原钙粘着蛋白蛋白质及其应用
CN1173033C (zh) Tnf/ngf超家族受体和可溶性寡聚tnf/ngf超家族受体的调节剂
CN1271387A (zh) 哺乳动物细胞因子∶白介素－b30和相关试剂
CN1222539C (zh) 人受体蛋白；相关的试剂和方法
CN1906297A (zh) Il－23及其受体、相关试剂和方法
CN1245534A (zh) 哺乳动物细胞表面抗原及相关试剂
CN1474869A (zh) 新型化合物
CN1493597A (zh) 分离树突状细胞膜蛋白基因
WO2001036467A2 (en) Mammalian receptor proteins; related reagents and methods
CN1444599A (zh) 新型化合物
CN1372594A (zh) Ox2受体的同系物
CN1245533A (zh) 哺乳动物趋化因子
CN1886155A (zh) 分离的哺乳动物膜蛋白基因和相关试剂
HK1085224A (en) Human receptor proteins; related reagents and methods
CN1242046A (zh) 与il10相关的哺乳动物细胞因子
CN1225130A (zh) 人类b细胞抗原,及相关试剂
HK1023600A (en) NEUTROKINEα
MXPA00008848A (en) Human receptor proteins;related reagents and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication